Format

Send to

Choose Destination
J Pharmacol Exp Ther. 2017 Aug;362(2):347-358. doi: 10.1124/jpet.117.240309. Epub 2017 Jun 9.

Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.

Author information

1
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.).
2
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany (A.H., C.K., Z.P.P.-G.); Graduate Research Training Program, PharMetrX, Berlin, Germany (A.H.); Department of Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland (M.J.); Department of Clinical Pharmacy, Institute of Pharmacy, Universitaet Bonn, Bonn, Germany (S.K., U.J.); and Institute of Mathematics, Universitaet Potsdam, Potsdam, Germany (W.H.) charlotte.kloft@fu-berlin.de zparra@unav.es.

Abstract

Paclitaxel is a commonly used cytotoxic anticancer drug with potentially life-threatening toxicity at therapeutic doses and high interindividual pharmacokinetic variability. Thus, drug and effect monitoring is indicated to control dose-limiting neutropenia. Joerger et al. (2016) developed a dose individualization algorithm based on a pharmacokinetic (PK)/pharmacodynamic (PD) model describing paclitaxel and neutrophil concentrations. Furthermore, the algorithm was prospectively compared in a clinical trial against standard dosing (Central European Society for Anticancer Drug Research Study of Paclitaxel Therapeutic Drug Monitoring; 365 patients, 720 cycles) but did not substantially improve neutropenia. This might be caused by misspecifications in the PK/PD model underlying the algorithm, especially without consideration of the observed cumulative pattern of neutropenia or the platinum-based combination therapy, both impacting neutropenia. This work aimed to externally evaluate the original PK/PD model for potential misspecifications and to refine the PK/PD model while considering the cumulative neutropenia pattern and the combination therapy. An underprediction was observed for the PK (658 samples), the PK parameters, and these parameters were re-estimated using the original estimates as prior information. Neutrophil concentrations (3274 samples) were overpredicted by the PK/PD model, especially for later treatment cycles when the cumulative pattern aggravated neutropenia. Three different modeling approaches (two from the literature and one newly developed) were investigated. The newly developed model, which implemented the bone marrow hypothesis semiphysiologically, was superior. This model further included an additive effect for toxicity of carboplatin combination therapy. Overall, a physiologically plausible PK/PD model was developed that can be used for dose adaptation simulations and prospective studies to further improve paclitaxel/carboplatin combination therapy.

PMID:
28600397
DOI:
10.1124/jpet.117.240309
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center